
Cancer Drug Resistance
@cdrjournal
Impact Factor 2024: 5.2 - Q1 (ONCOLOGY); CiteScore 2024: 8.3 - Q1 Pharmacology(medical). Indexed in PubMed Central(PMC), ESCI and Scopus #Cancer #DrugResistance
قد يعجبك
🎉 CDR Impact Factor hits 5.2! Now ranked Q1 in Oncology (64/326) ⬆️ Up 13% from last year (4.6) Proud to be the only journal focused on cancer drug resistance. Huge thanks to our contributors and our amazing Editorial Board!👏 🔗More details here: oaepublish.com/news/cdr.1218

🙌The new special topic is now accepting submissions! ✍️Key words: #UrologicalCancers; #DrugResistance 👉Guest Editors: @ Dr.William Cho; @DechaoF ; @UmberCheema; @UzoamakaOkoli2 ✉️Contacts: [email protected] 👋Welcome submissions!

🙌New publish in #Cancer #DrugResistance on 10 Oct. 👉Title: KLF5 promotes tumor proliferation and #oxaliplatin resistance via chromatin remodeling in KRAS-mutated #ColorectalCancer. 👀Read more: oaepublish.com/articles/cdr.2…

👏New publish in #Cancer #DrugResistance! 👉Key words: #PancreaticCancer, #Pancreaticductal #Adenocarcinoma, epithelial-to-mesenchymal transition 🤚Read more: oaepublish.com/articles/cdr.2…

👉New publish in #Cancer #DrugResistance! 👏Title: #Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest #transcriptomics rather than poor drug uptake 👉Read: oaepublish.com/articles/cdr.2…

👏New Special Issue in #Cancer #Drug #Resiatance! 🙌Topic: Deciphering Therapeutic Resistance in #UrologicalCancers: Bridging Clonal Evolution, Microenvironment, and Multi-Omics for Clinical Translation 👉Read more: oaepublish.com/specials/cdr.1…

✨Good new: 52 Editorial Board Members of Cancer Drug Resistance Recognized in the "World's Top 2% Scientists 2025" List! 👏Prestigious Honor、 Global Impact、 Reinforcing the Journal's Influence in the Field! 👉Read more: oaepublish.com/news/cdr.1348



👏New publish in #Cancer #DrugResistance! 👉Title: Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors 👋Read more: oaepublish.com/articles/cdr.2…

👏New publish in #Cancer #DrugResistance! 👉Title: Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant #bladdercancer cell lines 🙏Read more: oaepublish.com/articles/cdr.2…

🌟New Publication in #Cancer #DrugResistance! ☀️Title: #Immune #checkpoint #inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies 👉Read more: oaepublish.com/articles/cdr.2…

📢 Newly Published Research in #Cancer #DrugResistance This study develops an integrated #PrognosticModel combining #TRAG signature, #TILs, and clinical features to guide personalized adjuvant #therapy. Read and download for free: f.oaes.cc/xmlpdf/publish…

📢Newly Published Review in #Cancer #DrugResistance Can nanomedicine overcome hypoxia-driven immunotherapy resistance? The aim of this review: to bridge mechanistic insights with nanotechnology-enabled therapeutic solutions Read and download for free: f.oaes.cc/xmlpdf/publish…

📢 Newly Published Research How does #Cryptotanshinone selectively induce #CellDeath in #pancreatic #cancer? Explore the latest research for novel therapeutic insights! 📖Read and download for free: f.oaes.cc/xmlpdf/publish…

🌟New publish in #Cancer #DrugResistance! ☀️Title: Resistance signatures manifested in early drug response across cancer types and species ✉️Read more: oaepublish.com/articles/cdr.2…

👉New publish in #Cancer #DrugResistance about #PancreaticCancer! 👏Title: Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells 👐Read more: oaepublish.com/articles/cdr.2…

🙌New publish on 2 Sep. in #Cancer #DrugResistance! 🔦Keywords: #Immunotherapy resistance, HIF-1α, tumor-associated macrophages, T cell exhaustion, immune evasion, vascular normalization, #nanomedicine 👉Read more: oaepublish.com/articles/cdr.2…

📢 Newly Published Review in #Cancer #DrugResistance How can we overcome #ALK-targeted #therapy resistance in #LungCancer? 📖 Read for free: oaepublish.com/articles/cdr.2… 🔗Download PDF: f.oaes.cc/xmlpdf/publish…

🚀 Cancer Drug Resistance (CDR) – 2025 Second Round of Early-Career Editorial Board(ECEB) Recruitment! Join our ECEB & advance #Cancer #DrugResistance research! ✅ IF 5.2 | CiteScore 8.3 | Q1 Journal 📌 Apply now: docs.google.com/forms/d/e/1FAI… 🔍 Details: oaepublish.com/news/cdr.1292

🎉 Celebrate #OAE ’s 10th #Anniversary with #Cancer #DrugResistance – Enjoy a $400 #APC #Discount! 📅 Sep 1–Dec 31, 2025 (UTC) 💰 $400 off APC: $2,800 → $2,400 📄 All submissions eligible 📢Submit your research now! 🔗 Read the full announcement: oaepublish.com/news/cdr.1291

⁉️How do #ROS1 mutations shape the #immune landscape and drive #resistance to #immunotherapy in #HeadAndNeckCancer? 👉Discover this impactful research published in #Cancer #DrugResistance Read and download for free: f.oaes.cc/xmlpdf/publish…

🔦A publish about natural #sesquiterpenelactones in #Cancer #DrugResistance. 👉Title: Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways 🙌Read more: oaepublish.com/articles/cdr.2…

United States الاتجاهات
- 1. James Franklin 42.9K posts
- 2. Drake Maye 13.3K posts
- 3. George Pickens 7,114 posts
- 4. Cowboys 44.5K posts
- 5. Jets 103K posts
- 6. Penn State 58.7K posts
- 7. Rico Dowdle 3,543 posts
- 8. Justin Fields 21.8K posts
- 9. Steelers 48.4K posts
- 10. Colts 43.9K posts
- 11. Cooper Rush 2,747 posts
- 12. Zay Flowers 1,914 posts
- 13. Puka 7,927 posts
- 14. #Browns 2,861 posts
- 15. Eberflus 2,051 posts
- 16. #RavensFlock 2,276 posts
- 17. Diggs 6,050 posts
- 18. Rodgers 7,278 posts
- 19. Derrick Henry 2,799 posts
- 20. Broncos 45.1K posts
قد يعجبك
-
Arndt Vogel
@ArndtVogel -
Vivek Subbiah, MD
@VivekSubbiah -
Cowboyw2b
@Cowboyw2b2 -
Clarissa Mathias
@clarissamathias -
Guilherme Nader Marta
@GuiNaderMarta -
Oscar Arrieta
@ogarrieta -
giuseppe viscardi
@giusvisc -
Laura Mazzeo, MD
@mazzeolaure -
Dr. Iván R. González
@Dr_Ivanoncologo -
Tiffany
@tikiangels2 -
OncoViews
@OncoViews -
Angelo Dipasquale
@AngeloDipa_ -
Valerio Gristina
@VGristina -
Journal of Experimental & Clinical Cancer Research
@JournalofExper1 -
Oncoinfo
@Oncoinfo_it
Something went wrong.
Something went wrong.